Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Other |
| |
| 2 | Active Comparator |
| |
| 3 | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Drug | Solution, i.v infusion, 0 mg, Days 1 & 15 then monthly, 10 months. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Preliminary efficacy- Reduction in cumulative nr of new or recurrent Gd-enhancing lesions. |
| Measure | Description | Time Frame |
|---|---|---|
| Preliminary efficacy: 1) Decrease in annualized relapse rate and 2) Reduction in cumulative nr of new or enlarging T2-weighted MRI lesions. |
Not provided
Inclusion
Exclusion
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | New Haven | Connecticut | United States | |||
| Local Institution |
Not provided
Not provided
Not provided
Not provided
Not provided
| BMS 188667 (Abatacept) |
| Drug |
Vial, i.v infusion, 2mg/kg, Days 1 & 15 then monthly, 10 months. |
|
|
| BMS 188667 (Abatacept) | Drug | Vial, i.v infusion, 10 mg/kg, Days 1 & 15 then monthly, 10 months. |
|
|
| Louisville |
| Kentucky |
| United States |
| Local Institution | Worcester | Massachusetts | United States |
| Local Institution | Newark | New Jersey | United States |
| Local Institution | New York | New York | United States |
| Local Institution | Charlotte | North Carolina | United States |
| Local Institution | Philadelphia | Pennsylvania | United States |
| Local Institution | Dallas | Texas | United States |
| Local Institution | Burlington | Vermont | United States |
| Local Institution | Madison | Wisconsin | United States |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069594 | Abatacept |
| ID | Term |
|---|---|
| D018796 | Immunoconjugates |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D012712 | Serum Globulins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D005916 | Globulins |
Not provided
Not provided